العربية
Part of the Master Guide

Arthritides Explained: Symptoms, Diagnosis, and Treatment Options

Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition

30 مارس 2026 11 min read 89 Views
Illustration of rheumatoid arthritis rheumatoid - Dr. Mohammed Hutaif

Key Takeaway

Learn more about Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition and how to manage it. Rheumatoid arthritis is the most common inflammatory arthritis, affecting 0.5–1% of the population, predominantly young adult women. This rheumatoid condition presents with insidious subacute onset, morning stiffness, and polyarthritis, often in hands and feet. Diagnosis utilizes criteria including joint involvement, duration, and positive lab tests for rheumatoid factor and anti-CCP antibodies.

  1. Rheumatoid arthritis (see Table 1.20)
  2. Most common inflammatory arthritis
  3. Affects 0.5%–1% of population; three times more common in women
  4. 15% concordance rate in monozygotic twins
  5. Clinical presentation (see Fig. 1.32)
  6. Insidious subacute onset over 6 weeks
  7. Fatigue, malaise, anemia
  8. Morning stiffness and polyarthritis with swelling
  9. Hand and foot deformities are most common and are discussed in respective subsequent chapters
  10. Also common in the knees, elbows, shoulders, ankles, and cervical spine
  11. Subcutaneous rheumatoid nodules ( Fig. 1.34)
  12. Juxtaarticular erosions and periarticular osteopenia on radiographs
  13. 2010 American College of Rheumatology Classification Criteria for RA are summarized in Table 1.21.
  14. Diagnosis requires score 6 or more
  15. Criteria include
  16. Number of joints involved and duration of involvement
  17. Positive laboratory test results often found
  18. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)
  19. Pathogenesis
  20. Rheumatoid factor (RF) titer
  21. Antibody (immunoglobulin [Ig] M) against the Fc (crystallizable fragment) portion of IgG
  22. Positive result in about 80%
  23. Test for anticyclic citrullinated protein (anti-CCP) antibodies
  24. Also known as anti-CCP antibodies (ACPAs)
  25. Most sensitive and specific test (≈90% specific)
  26. Presence linked to more aggressive disease
  27. T cell–mediated immune response from an infectious or environmental antigen (smoking is one known trigger) in a genetically susceptible individual (HLA-DR4 and HLA-DW4)
  28. Mononuclear cells are primary mediator of RA tissue damage
  29. Initial response in soft tissues— neovascularization and synovitis
  30. CD4+ T lymphocytes (helper cells) activate synovial cells through direct cell-cell contact
  31. Synoviocytes produce cytokines
  32. Macrophages (type A): main source for TNF-α, IL-1
  33. Fibroblast (type B): main source for MMPs, proteases, and RANKL
  34. B lymphocytes (plasma cells): make RF, anti-CCP antibodies
  35. TNF-α, IL-1, IL-6, IL-7 upregulated
  36. IL-1: Regulator of inflammation and matrix destruction
  37. TNF-α:
  38. Upregulates endothelial adhesion molecules and stimulates angiogenesis
  39. Table 1.20
    Comparison of Common Arthritides Age Incidence Arthritis Group By Sex Affected ---
    Noninflammatory Osteoarthritis | Elderly
    | M > F Neuropathic | Elderly
    | M > F Acute rheumatic fever | Children
    | M = F Ochronosis | Adults
    | M = F
    Inflammatory Rheumatoid | Young
    adults
    | F > M Systemic lupus erythematosus | Young
    adults
    | F > M Juvenile rheumatoid arthritis | Children
    | F > M Relapsing polychondritis | Elderly
    | M = F
    Spondyloarthropathies Ankylosing spondylitis | Young
    adults
    | M > F
    | | Reactive arthritis (Reiter syndrome) | Young
    adults
    | M > F
    | ---|---|---| Psoriatic | Young
    adults
    | M = F Enteropathic | Young
    adults
    | M > F Age Incidence Arthritis Group By Sex S Affected ---
    Crystal Deposition Disease Gout | Young
    | M > F
    | Chondrocalcinosis | Elderly
    | M = F
    | Infectious Pyogenic | All
    | M = F
    | Tuberculous | Elderly
    | M > F
    | Lyme disease | Young
    | M = F
    | Fungal | All
    | M > F
    | Hemorrhagic Hemophilia | Young
    | M
    | Sickle cell disease | Young
    | M = F
    | Pigmented villonodular synovitis | Young
    | M = F
    | ↓ , Decreased; AFB, acid-fast bacilli; ASO, antistreptolysin O; CPK, creatine phosphokinase; PTT, partial thromboplastin time.
    Illustration 1 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    --- FIG. 1.30 Enzyme cascade of IL-1–stimulated degradation of articular cartilage. TPA, Tissue plasminogen activator. From Simon SR, editor: Orthopaedic basic science, Rosemont, IL, 1994, American Academy of Orthopaedic Surgeons, p 40.
    Illustration 2 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    --- FIG. 1.31(A) Radiograph showing joint space narrowing, osteophytes, and bony sclerosis. (B) Macrosection of an osteoarthritic human femoral head demonstrating subarticular cysts, sclerotic bone formation, and a superior femoral head osteophyte. (C) Low-power micrograph of osteoarthritis showing fibrillation, fissures, and cartilage loss. D, Gross pathology of femoral head demonstrating cartilage thinning (1) ,
    subarticular cyst (2
    [“geode”]), and normal hyaline cartilage remaining (3) . A Courtesy Marc DeHart, MD, and Texas Orthopedics; B from Simon SR, editor: Orthopaedic basic science, Rosemont, IL, 1994, American Academy of Orthopaedic Surgeons; C and D from Horvai A: Bones, joints, and soft tissue tumors. In Kumar V et al, editors: Robbins and Cotran pathologic basis of disease, ed 9,
    Philadelphia, 2015,
    Elsevier, Fig. 26-93.
    Illustration 3 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    --- FIG. 1.32 Differences between rheumatoid arthritis and osteoarthritis. Left side of illustration demonstrates the main historical characteristics of RA, including symmetric involvement (both right and left joints as well as both medial and lateral compartments of the knees). Bilateral hand involvement is characteristic and usually involves wrist joints and proximal metacarpal joints. Right side of figure demonstrates osteoarthritis, which often is much more severe in one joint or one compartment of the knee. Hand involvement more commonly involves the distal interphalangeal joints (Heberden nodes) and proximal interphalangeal joints (Bouchard nodes) joints as well as the base of the thumb.
  40. Promotes influx of leukocytes and activates synovial fibroblasts
  41. Later response
  42. Promotes pain receptor pathways
  43. Drives osteoclastogenesis
  44. Synovial cells invade cartilage “pannus” and release MMPs, causing chondrolysis
  45. Periarticular bone erosions
  46. Cytokines stimulate osteoblasts and synovial B cells to make RANKL, which joins with RANK to activate osteoclasts. Responsible for bone destruction.
  47. Osteoclasts secrete cathepsin K and carbonic anhydrase.
    Illustration 4 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 5 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 6 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 7 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition FIG. 1.33 Neuropathic arthritis. Arthritic degeneration due to lack of sensation can be caused by many diseases. All share radiographic findings that are more severe than the symptoms (often painless) and the fragments from bony destruction. Often findings take many years to develop. (A and B) Diabetic Charcot arthropathy of the foot is easily recognized by most of the industrialized world. (C and D) The most common cause of upper extremity neuropathic joint is syringomyelia ( syrinx = fluid-filled sac in central cord that causes insidious loss of pain and temperature early). (E–G) Tabetic arthropathy (tertiary syphilis) is the most common neuropathic arthritis of the knee and can often involve the hip.
    From Yablon CM et al: Areview of Charcot neuroarthropathy of the midfoot and
    hindfoot: what every radiologist needs to know, Curr Probl Diagn Radiol 39:187–199, 2010; Atalar AC et al: Neuropathic arthropathy of the shoulder associated with syringomyelia: a report of six cases, Acta Orthop Traumatol Turc 44:328–336, 2010; and Allali F et al: Tabetic arthropathy. Areport of 43 cases, Clin Rheumatol 25:858–860, 2006.
    Illustration 8 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 9 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 10 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 11 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition FIG. 1.34 Upper extremity changes in common arthritis types. Left side of figure shows rheumatoid changes. (A) Swan neck deformity of index, middle, and ring fingers, with PIP joints extended and DIP joints flexed. (B) Boutonnière deformity: PIP joints flexed, DIP joints extended. (C) Bilateral wrist swelling with both ulnar metacarpal phalangeal joint deformities and swan neck deformities of fingers and left thumb. (D) Rheumatoid nodes noted on posterior olecranon region. Right side of figure shows osteoarthritic changes. (E) DIP changes (Heberden nodes) and PIP changes (Bouchard nodes). (F) Radiograph showing osteoarthritic changes at the base of the thumb. From O’Dell JD: Rheumatoid arthritis. In Goldman L, Schafer AI, editors: Goldman-
    Cecil medicine, Philadelphia, 2016, Elsevier, Fig. 264-3; Sweeney SE et al: Clinical features of rheumatoid arthritis. In Firestein GS et al: Kelley’s textbook of rheumatology, Philadelphia, 2013, Elsevier, Fig. 70-4; and http://medsci.indiana.edu/c602web/602/c602web/jtcs/docs/heber1.html
  48. Systemic manifestations
  49. Rheumatoid vasculitis
  50. Distal splinter hemorrhage
  51. Cutaneous ulcers (pyoderma gangrenosum)
  52. Visceral arteritis
  53. Pericarditis and pericardial effusion
  54. Pulmonary disease including nodules and fibrosis
  55. Felty syndrome: severe erosive RA with splenomegaly and leukopenia
  56. Treatments and their perioperative considerations
  57. Regimen variable and often employs multiple agents
  58. NSAIDs: help symptoms early—antiinflammatory effects
  59. Should be held for 7–10 days preoperatively.
  60. Low-dose steroids
  61. Decrease prostaglandins and leukotrienes
  62. Used initially as “bridge therapy” to disease-modifying antirheumatic drugs (DMARDs)
  63. “Stress dose” steroid should be used perioperatively for patients on longterm steroid therapy
  64. DMARDs
  65. Intended to address underlying autoimmune response
  66. Conventional DMARDs take 2–6 months to work
  67. Methotrexate: folate analogue
  68. Inhibits purine metabolism and T-cell activation
  69. Inhibits neovascularization
  70. Adverse reactions (ADRs): toxic to bone marrow, liver, and lung
  71. Usually can continue through surgery
  72. Azathioprine: immunosuppressive agent
  73. ADR: neutropenia
  74. Cyclosporine: immunosuppressive agent
  75. Inhibits activation of
    CD4+ T cells
  76. ADRs: nephrotoxicity, neurotoxicity, gingival hyperplasia
  77. Hydroxychloroquine (Plaquenil)
  78. Inhibits toll-like receptor 9 (TLR9)
  79. ADR: retinal toxicity (requires ophthalmology followup)
  80. Table 1.21 The 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis Criteria Score ---
    A. Joint Involvement 1 Large Joint | 0 2–10 Large Joints | 1 1–3 Small Joints | 2 4–10 Small Joints | 3 > 10 Joints (at least 1 small joint) | 5
    B. Serology (at least 1 test result is needed) Negative RF and negative ACPA | 0 Low-positive RF or low-positive ACPA | 2 High-positive RF or high-positive ACPA | 3
    C. Acute-Phase Reactants (at least 1 test result is needed) Normal CRP and normal ESR | 0 Abnormal CRP or abnormal ESR | 1
    D. Duration of Symptoms < 6 weeks | 0 > 6 weeks | 1
    From Aletaha D et al: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative, Arthritis Rheum 62:2569–2581, 2010.
  81. Usually can continue through surgery
  82. Sulfasalazine
  83. Decreases synthesis of inflammatory mediators
  84. ADRs: granulocytopenia, hemolytic anemia (glucose-6-phosphate dehydrogenase [G6PD])
  85. Usually can continue through surgery
  86. Minocycline
  87. Inhibits MMP collagenase
  88. ADR: cutaneous hyperpigmentation
  89. Biologic DMARDs
  90. Target TNF-α: etanercept, infliximab, adalimumab

  91. Targets IL-1: anakinra

  92. Targets CD20: rituximab
  93. Surgery should be scheduled at end of dosing cycle (e.g., in a patient taking etanercept schedule, surgery should occur the second week after the first withheld dose).
  94. Risks of opportunistic infection and lymphoma

  95. Surgical treatment is discussed within respective chapters.
  96. Juvenile idiopathic arthritis (JIA) is discussed in Chapter 3, Pediatric Orthopaedics.
  97. Systemic lupus erythematosus ( Fig. 1.35 ; see Table 1.20)
  98. Chronic inflammatory disease of unknown origin
  99. 90% of cases in women (blacks > whites)
  100. Initially mediated by tissue-binding autoantibodies and immune complexes (type III hypersensitivity)
  101. Pathophysiology
  102. Susceptible genetics stimulated by environment
  103. Immune system autoregulatory failure
  104. Sustained production of antibody to self-antigens
  105. Antinuclear antibodies (ANAs)—best screen; positive in 95%
  106. Anti-dsDNA, anti-Sm, anti-La (SS-B), antihistone antibodies—drug-induced lupus
  107. Immune complexes accumulate in various tissues and cause chronic inflammation
  108. Clinical findings
  109. Skin/joints—rash and arthritis
  110. Heart/kidney—pericarditis/nephritis
  111. Blood vessels—vasculitis
  112. Bone and joint involvement—most common feature
  113. Nonerosive polyarthritis affects over 75% (hand and wrist most common).
  114. Osteonecrosis (especially with steroids)
  115. Butterfly malar rash—classic feature
  116. Fever, pancytopenia
  117. Pharmacologic treatment similar to that for RA.
  118. Seronegative spondyloarthropathies
  119. Characterized by negative RF titer result and, often, positive HLA-B27 test result
  120. Symptoms
  121. Inflammatory back pain
  122. Peripheral arthritis
  123. Enthesitis—heel pain
  124. Dactylitis—sausage digit
  125. Eye—uveitis (iritis), conjunctivitis
  126. Skin, mucosal, GI, urethral
  127. Similar treatment routines, including NSAIDs, steroids, and DMARDs
  128. Ankylosing spondylitis (AS) ( Fig. 1.36 ; see Table 1.20)
  129. Male/female ratio 3:1; ages 20–40 years
  130. Most common in Northern European whites
  131. 90% HLA-B27 positive ( Table 1.22)
  132. Symptoms and findings
  133. Bilateral sacroiliitis (earliest symptom)
  134. Improves with exercise, not better with rest, pain at night
  135. Associated morning stiffness
  136. Progressive spinal flexion deformities over life
  137. Chin-on-chest deformity
  138. Modified Schober test (loss of lumbar flexion) (see Fig. 1.36C)
  139. Two marks are made10 cm apart over lumbar spine in erect patient.
  140. With patient in maximum spinal
    flexion, increase of less than 4 cm between marks indicates loss of flexion.
  141. Hip involvement at young age—poor prognosis
  142. Enthesitis: inflammation of tendon insertion
  143. Loss of chest expansion
  144. Uveitis: red, painful eye in 40%
  145. Aortic insufficiency and heart block
  146. Radiographic changes
  147. Squaring of the vertebrae
  148. Vertical syndesmophytes
  149. Bamboo spine
  150. Autofusion of sacroiliac joints (see Fig. 1.36B)
  151. Whiskering of the entheses
  152. Surgical treatment for AS is discussed within Chapter 8, Spine.
  153. Reactive arthritis (Reiter syndrome) ( Fig. 1.37 ; see Table 1.20)
  154. Classical triad presentation: “Can’t see, can’t pee, can’t climb a tree.”
  155. Young white males (18–40 years)
  156. Follows an infection at another site (hence “reactive”)
  157. Chlamydia, Shigella, Yersinia, Salmonella
  158. Findings
  159. Conjunctivitis, urethritis, and oligoarticular arthritis
    Illustration 12 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 13 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition FIG. 1.35 Systemic lupus erythematosus. (A) Autoantibodies to DNA and DNA-binding proteins form immune complexes that stimulate immune system–directed inflammation throughout the body (type III hypersensitivity reaction). (B) Direct immunofluorescence with anti–immunoglobulin G antibodies shows immune complex deposits at two different places: a bandlike deposit along the epidermal basement membrane—positive result of lupus band test—and within the nuclei of the epidermal cells (ANAs). (C) Most patients have skin and joint involvement. The classic butterfly rash of SLE occurs in 10%–50% of patients with acute SLE. (D) The same immune complexes are seen in the basement membrane of the renal glomerulus. (E) Flea-bitten appearance of kidney specimen, with lupus nephritis causing various degrees of proteinuria, hematuria, and cellular casts. From Habif TP: Clinical dermatology, ed 5, St Louis,
    Mosby/Elsevier, 2009; Wikimedia Commons: Diffuse proliferative lupus nephritis.
    http://en.wikipedia.org/wiki/Lupus_nephritis#mediaviewer/File:Diffuse_pr oliferat
    ; and Wikimedia Commons: Lupus band test. http://en.wikipedia.org/wiki/Systemic_lupus_erythematosus#mediaviewer/File:L
  160. Sudden asymmetric swelling and pain in knee , ankle, hip
  161. May persist 3–5 months
  162. Feet affected more often than hands (heel pain)
  163. Calcaneal periostitis and metatars al head erosion
  164. Dactylitis: sausage digit of one finger/toe (see Fig.
    1.37E)
  165. 60% of patients with chronic disease have sacroiliitis.
  166. Painless mucocutaneous ulcers (penile) and oral stomatitis (see Fig. 1.37B)
  167. Urethritis (dysuria), prostatitis, or cervicitis
  168. Pustular lesions on the extremities, palms, and soles (keratoderma blennorrhagicum)
  169. Treatment: NSAIDs and PT
    Illustration 14 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 15 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 16 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition
    Illustration 17 for Rheumatoid Arthritis: What You Need to Know About This Rheumatoid Condition FIG. 1.36 Ankylosing spondylitis is an axial seronegative spondyloarthropathy that causes progressive cervical and thoracic kyphosis and bamboo spine but has earliest involvement in the sacroiliac joints. (A) Early sacroiliitis demonstrated by loss of clarity and sclerosis in the lower third of the sacroiliac joints, particularly affecting the iliac side of the right sacroiliac joint (hip joints are normal). (B) Advanced disease with ankylosis or fusion of both the sacroiliac and hip joints. (C) Schober test; two marks made 10 cm apart on lumbar spine in erect stance should be less than 14 to 15 cm during forward flexion.
    From Raychaudhuri S: The classification and diagnostic criteria of ankylosing spondylitis, J
    Autoimmun 48–49:128–133, 2014.
  170. Psoriatic arthropathy (PsA) (see Table 1.20)
  171. Affects 5%–30% of patients with psoriasis
  172. Usually skin disease precedes arthritis
  173. Men and women (aged 30–40 years) equally affected
  174. Characteristic changes
  175. Distal interphalangeal (DIP) involvement (rare in other inflammatory arthritides)
  176. Nail changes in 90%
  177. Pitting, fragmentation, and discoloration
  178. 30% have sausage digits
  179. Prominent enthesitis and tenosynovitis
  180. Arthritis mutilans—most destructive form
  181. Telescoping (shortening) of digits
  182. Pathophysiology
  183. Upregulated RANKL in synovium (B-type cells)
  184. Marked increase in osteoclast precursors
  185. Radiographic findings
  186. Pencil-in-cup deformity, DIP
  187. Small joint ankylosis
  188. Osteolysis of metacarpal (MC) and phalangeal bone
  189. Periostitis and bony enthesitis
  190. Enteropathic arthritis (see Tables 1.20 and 1.22)
  191. Arthritis in presence of inflammatory bowel disease
  192. Varied clinical picture, but joint erosions uncommon
  193. 10%–50% of patients experience peripheral joint arthritis.
  194. Acute monoarticular synovitis precedes bowel symptoms.
  195. Nondeforming arthritis
  196. More common in large weight-bearing joints
  197. 10%–15% of cases associated with ankylosing spondylitis

You Might Also Like

Dr. Mohammed Hutaif
Medically Verified Content by
Prof. Dr. Mohammed Hutaif
Consultant Orthopedic & Spine Surgeon
Chapter Index